BRIEF published on 11/26/2025 at 00:51, 9 days 4 hours ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 9 days 4 hours ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 10 days 16 hours ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 10 days 16 hours ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 3 months 20 days ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
PRESS RELEASE published on 08/15/2025 at 13:27, 3 months 20 days ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 3 months 28 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 3 months 28 days ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 5 months 10 days ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 5 months 10 days ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
Published on 12/05/2025 at 02:35, 2 hours 53 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 28 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 23 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 28 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 57 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 37 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 2 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 12 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 17 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 28 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 43 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 43 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 27 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
